Tweedy Browne Co LLC Decreases Stock Position in Envista Holdings Co. (NYSE:NVST)

Tweedy Browne Co LLC cut its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 19.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,528,831 shares of the company's stock after selling 358,589 shares during the quarter. Envista accounts for 2.0% of Tweedy Browne Co LLC's investment portfolio, making the stock its 12th largest holding. Tweedy Browne Co LLC owned about 0.89% of Envista worth $29,491,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Venturi Wealth Management LLC lifted its position in shares of Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after acquiring an additional 1,638 shares during the period. GAMMA Investing LLC increased its stake in Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Envista during the fourth quarter valued at about $53,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Envista during the 4th quarter worth about $86,000. Finally, KBC Group NV grew its stake in shares of Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after buying an additional 3,082 shares during the period.

Analyst Ratings Changes

Several brokerages have issued reports on NVST. JPMorgan Chase & Co. cut their price target on Envista from $20.00 to $19.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. New Street Research set a $19.00 target price on Envista in a research report on Thursday, March 6th. Needham & Company LLC reissued a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Jefferies Financial Group upped their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Finally, UBS Group reduced their price objective on shares of Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Monday, March 10th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Envista has an average rating of "Hold" and a consensus target price of $20.18.

Remove Ads

Envista Stock Performance

Envista stock traded down $0.63 during mid-day trading on Friday, reaching $15.47. 5,800,011 shares of the company's stock were exchanged, compared to its average volume of 2,452,247. The firm has a market capitalization of $2.66 billion, a PE ratio of -2.38, a P/E/G ratio of 1.27 and a beta of 1.12. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The business's fifty day simple moving average is $19.18 and its 200 day simple moving average is $19.53. Envista Holdings Co. has a one year low of $14.77 and a one year high of $23.00.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, sell-side analysts expect that Envista Holdings Co. will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.